Enabling clinical use of foundation models in histopathology

📅 2026-02-25
📈 Citations: 0
Influential: 0
📄 PDF
🤖 AI Summary
This study addresses the vulnerability of foundation models in computational pathology to pre-analytical and technical variations—such as tissue processing protocols and scanner differences—which introduce prediction bias in downstream tasks and hinder clinical deployment. To mitigate this, the authors propose a novel robustness-oriented loss function that, without retraining the foundation model, enhances downstream training by steering the model toward biologically relevant features while reducing sensitivity to technical artifacts. The approach is rigorously evaluated across eight state-of-the-art histopathology foundation models using 27,042 whole-slide images from 6,155 patients, with thousands of downstream models systematically trained and assessed. Results demonstrate substantial improvements in generalization and predictive accuracy on real-world data, offering an efficient and practical pathway toward clinically viable computational pathology systems.

Technology Category

Application Category

📝 Abstract
Foundation models in histopathology are expected to facilitate the development of high-performing and generalisable deep learning systems. However, current models capture not only biologically relevant features, but also pre-analytic and scanner-specific variation that bias the predictions of task-specific models trained from the foundation model features. Here we show that introducing novel robustness losses during training of downstream task-specific models reduces sensitivity to technical variability. A purpose-designed comprehensive experimentation setup with 27,042 WSIs from 6155 patients is used to train thousands of models from the features of eight popular foundation models for computational pathology. In addition to a substantial improvement in robustness, we observe that prediction accuracy improves by focusing on biologically relevant features. Our approach successfully mitigates robustness issues of foundation models for computational pathology without retraining the foundation models themselves, enabling development of robust computational pathology models applicable to real-world data in routine clinical practice.
Problem

Research questions and friction points this paper is trying to address.

foundation models
histopathology
technical variability
robustness
computational pathology
Innovation

Methods, ideas, or system contributions that make the work stand out.

foundation models
histopathology
robustness loss
computational pathology
technical variability
🔎 Similar Papers
No similar papers found.
A
Audun L. Henriksen
Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway
O
Ole-Johan Skrede
Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway
L
Lisa van der Schee
Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands
E
Enric Domingo
Department of Oncology, University of Oxford, Oxford, UK
S
Sepp De Raedt
Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway
I
Ilyá Kostolomov
Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway
Jennifer Hay
Jennifer Hay
Professor of Linguistics, University of canterbury
linguistics phonetics phonology
K
Karolina Cyll
Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway
W
Wanja Kildal
Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway
J
Joakim Kalsnes
Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway
R
Robert W. Williams
Area for Improvement and Digital Transformation, Norwegian Offshore Directorate, Stavanger, Norway
M
Manohar Pradhan
Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway
J
John Arne Nesheim
Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway
H
Hanne A. Askautrud
Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway
M
Maria X. Isaksen
Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway
K
Karmele Saez de Gordoa
Pathology Department, Hospital Clínic, Barcelona, Spain
M
Miriam Cuatrecasas
Pathology Department, Hospital Clínic, Barcelona, Spain
J
Joanne Edwards
School of Cancer Sciences, Wolfson Wohl Cancer Research Centre, University of Glasgow, Glasgow, UK
T
TransSCOT group
A
Arild Nesbakken
Institute of Clinical Medicine, University of Oslo, Oslo, Norway
N
Neil A. Shepherd
Gloucestershire Cellular Pathology Laboratory, Cheltenham General Hospital, Cheltenham, UK
I
Ian Tomlinson
Department of Oncology, University of Oxford, Oxford, UK
D
Daniel-Christoph Wagner
Institute of Pathology, University Medical Center, Mainz, Germany
R
Rachel S. Kerr
Department of Oncology, University of Oxford, Oxford, UK
T
Tarjei Sveinsgjerd Hveem
Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway